Company intelligence / Profile preview
Caregen Co., Ltd.
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
Overview
Caregen has developed and commercialized over 600 functional peptides used in cosmeceuticals, Class III medical devices, food supplements, and pharmaceuticals. Their products are marketed globally in more than 130 countries. The company’s unique skin delivery technology maximizes the efficacy of their peptide-based products. Notably, their PTx platform is the first to utilize a Botulinum Toxin Type C mechanism for topical use targeting hyperhidrosis, pain, and skin diseases. Most programs are at commercial stage with ongoing R&D into new indications.[6]
- Therapeutic areas
- NeurologyDermatology
- Modalities
- Peptides (biomimetic and hybrid)Small molecules (limited, per R&D focus)[7]
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Caregen Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Caregen Co., Ltd..